Pharma Leaders

IMU-856: A Potential Solution for Celiac Patients Facing Cross-Contamination Risks

15 hours ago
Add Comment
by David Miller
945 Views

Daniel Vitt, CEO, Immunic Therapeutics, discusses how IMU-856 could support the challenges of gluten-free diets and cross-contamination risks for celiac disease.

Daniel Vitt, CEO, Immunic Therapeutics, discusses how IMU-856 could support the challenges of gluten-free diets and cross-contamination risks for celiac disease.

You may also like

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

View all posts

Leave a Comment

Don`t Leave Yet!

Thank you!

[mwai_chat window="true" fullscreen="true"]